concern about, maybe I am missing something but I don’t have too much concern about
combining the long-term and short-term in this case. You know, from what I understand
randomization was retained, blinding was retained, and it was a mixture between patients
who simply continued the short-term and those who had glycemic rescue. I am not
seeing a major problem with combining these populations. I don’t know what others
by saying I think the fact that they were rescued means that they didn’t respond very well
to the first therapy. So it does potentially alter the long-term therapy and I think we heard
some statistical analyses that try to take those into account. The trials are imperfect but
nonetheless in the real world seem reasonable. So does anybody have any further
discussion on, important discussion on the long-term assessments and how they were
issue that Michael brought up of, what are the cardiovascular effects of the other
medications? So it is kind of beginning to mix apples and oranges a little bit but some
people are going through one treatment and some people are really not on the treatment
they were originally randomized, so they have added another treatment that may also
affect their cardiovascular risk. So I think it just muddies the waters a little bit.
This question is open for a discussion. Well, I can start the discussion
DR. KONSTAM: Well, you know, I guess I just don’t have too much
DR. BURMAN: Dr. Flegal?
DR. FLEGAL: Well, I also, I don’t see a major problem but there is the
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
DR. BURMAN: Mike.
DR. PROSCHAN: Yeah, I think from the standpoint of the HbA1c and
the short-term trial, when I first looked in the booklet and I saw that it said, ‘all the